ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 027,33
0,38%
Dow Jones
38 852,27
0,46%
DAX
18 296,70
0,69%
Brent Oil
83,255
-0,26%
Bitcoin
64 191,49
1,62%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. Armata Pharmaceuticals Inc (ARMP)

  7. Armata Pharmaceuticals Inc (ARMP) Actualités

ARMP

Armata Pharmaceuticals (ARMP)

Armata Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:AMEX:ARMP
DateHeureSourceTitreSymboleSociété
04/03/202423h35Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]AMEX:ARMPArmata Pharmaceuticals Inc
04/03/202422h03Edgar (US Regulatory)Form 8-K - Current reportAMEX:ARMPArmata Pharmaceuticals Inc
23/01/202422h17Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansAMEX:ARMPArmata Pharmaceuticals Inc
27/12/202303h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ARMPArmata Pharmaceuticals Inc
23/09/202301h17Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:ARMPArmata Pharmaceuticals Inc
14/08/202313h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:ARMPArmata Pharmaceuticals Inc
03/08/202322h37Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersAMEX:ARMPArmata Pharmaceuticals Inc
03/08/202322h35Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:ARMPArmata Pharmaceuticals Inc
03/08/202322h34Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:ARMPArmata Pharmaceuticals Inc
24/07/202322h30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsAMEX:ARMPArmata Pharmaceuticals Inc
27/06/202322h31Edgar (US Regulatory)Current Report Filing (8-k)AMEX:ARMPArmata Pharmaceuticals Inc
11/05/202322h07Edgar (US Regulatory)Quarterly Report (10-q)AMEX:ARMPArmata Pharmaceuticals Inc
16/03/202321h07Edgar (US Regulatory)Annual Report (10-k)AMEX:ARMPArmata Pharmaceuticals Inc
13/02/202321h42Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)AMEX:ARMPArmata Pharmaceuticals Inc
07/02/202322h01Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)AMEX:ARMPArmata Pharmaceuticals Inc
10/11/202212h25TipRanksH.C. Wainwright Keeps Their Buy Rating on Armata Pharmaceuticals (ARMP)AMEX:ARMPArmata Pharmaceuticals Inc
15/08/202213h45TipRanksLadenburg Thalmann & Co. Remains a Buy on Armata Pharmaceuticals (ARMP)AMEX:ARMPArmata Pharmaceuticals Inc
12/08/202212h25TipRanksH.C. Wainwright Sticks to Their Buy Rating for Armata Pharmaceuticals (ARMP)AMEX:ARMPArmata Pharmaceuticals Inc
01/08/202215h28TipRanksArmata Pharmaceuticals (ARMP) Receives a Buy from H.C. WainwrightAMEX:ARMPArmata Pharmaceuticals Inc
01/06/202212h03Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)AMEX:ARMPArmata Pharmaceuticals Inc
24/05/202212h02Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)AMEX:ARMPArmata Pharmaceuticals Inc
16/05/202212h45TipRanksArmata Pharmaceuticals (ARMP) Gets a Buy Rating from Ladenburg Thalmann & Co.AMEX:ARMPArmata Pharmaceuticals Inc
15/04/202221h57Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:ARMPArmata Pharmaceuticals Inc
01/04/202222h51Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)AMEX:ARMPArmata Pharmaceuticals Inc
18/03/202211h35TipRanksWall Street Analysts Are Bullish on Top Healthcare PicksAMEX:ARMPArmata Pharmaceuticals Inc
24/02/202222h07Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)AMEX:ARMPArmata Pharmaceuticals Inc
07/01/202213h55TipRanksLadenburg Thalmann & Co. Keeps Their Buy Rating on Armata Pharmaceuticals (ARMP)AMEX:ARMPArmata Pharmaceuticals Inc
05/01/202216h35TipRanksH.C. Wainwright Maintains Their Buy Rating on Armata Pharmaceuticals (ARMP)AMEX:ARMPArmata Pharmaceuticals Inc
22/04/202112h01Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)AMEX:ARMPArmata Pharmaceuticals Inc
21/04/202123h31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)AMEX:ARMPArmata Pharmaceuticals Inc
 Showing the most relevant articles for your search:AMEX:ARMP

Dernières Valeurs Consultées

NYSE
MCD
McDonalds
EU
VK
Vallourec
EU
AF
Air FranceKLM
NASDAQ
NVDA
NVIDIA
EU
CAP
Capgemini
EU
CS
Axa
NASDAQ
AAPL
Apple
FTSE
UKX
FTSE 100
EU
DG
Vinci
EU
ORA
Orange
NYSE
MRK
Merck
EU
MC
Lvmh Moet Hennessy Louis...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés